Oncology Best Practice™: Integrating Car-T Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know

Oncology Best Practice™:
Integrating Car-T Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668

Overview

This 1.0 AMA credit program will describe unique aspects of chimeric antigen receptor (CAR) T-cell therapy, including considerations in the timing of patient referrals. Expert faculty will provide updates of key clinical data supporting the use of CAR T cells in patients with relapsed/refractory lymphoid malignancies, including acute lymphoblastic leukemia and aggressive non-Hodgkin lymphoma. Additionally, this program will illustrate the characteristic adverse events associated with CAR T-cell therapy and strategies to manage these toxicities. The activity will utilize a variety of formats, including presentation of new data, clinical scenarios exploring the evidence behind treatment decisions, Q&A sessions to encourage peer-to-peer and peer-to-expert interactions, and the sharing of best practices.

Benefits of Attending

• Gain expert insights into the unique mechanism of action of CAR T cells
• Recognize the importance of early referral for candidates for CAR T-cell therapy
• Evaluate the clinical efficacy and safety of CAR T cells in patients with relapsed/refractory hematologic malignancies
• Learn how to diagnose and manage cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy

Target Audience

This educational activity is directed toward community oncologists and hematologists who treat patients with lymphoid malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lymphoid malignancies will be invited to participate.

Learning Objectives

• Recognize the unique mechanism of CAR T-cell action and the nuances of manufacture of CAR T-cell therapy
• Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment paradigms
• Explain pathways for the use of CAR T cells, including identification of eligible patients, process of referral to the treatment centers, and the importance of posttreatment follow-up
• Determine the potential CAR T-cell treatment-related toxicities and best practices for adverse event detection, grading, monitoring, management, and mitigation

Chair

Cameron Turtle, MBBS, PhD, FRACP, FRCPA
Attending Physician
Fred Hutch Bone Marrow Transplant Program & Seattle Cancer Care Alliance
Immunotherapy Service
Seattle, WA